A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

Author: Wierzbicki Rafal   Jonker Derek   Moore Malcolm   Berry Scott   Loehrer Patrick   Youssoufian Hagop   Rowinsky Eric  

Publisher: Springer Publishing Company

ISSN: 0167-6997

Source: Investigational New Drugs, Vol.29, Iss.1, 2011-02, pp. : 167-174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content